Rapid Dose Therapeutics Completes Amalgamation of Consolidated Craft Brands

BURLINGTON, Ontario, March 08, 2021 (GLOBE NEWSWIRE) — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), is a Canadian life sciences company focused on innovative drug and active ingredient delivery solutions. The flagship product ‘QuickStrip™’ is a thin, orally dissolvable film infused with an active ingredient (nutraceuticals, cannabis or pharmaceuticals) that is delivered quickly into the bloodstream bypassing first-pass metabolism resulting in rapid onset of the active ingredient.

The Company is announcing today that, further to its press release of January 11, 2021, it has signed the Amalgamation Agreement (“Amalgamation Agreement”) to acquire 2544737 Ontario Limited, operating as Consolidated Craft Brands (“CCB”), in a share transaction (the “Transaction”) totalling $5,000,000 CDN. (Five million dollars Canadian). The Transaction is an acquisition by RDT of CCB with CCB being amalgamated into a newly created subsidiary of RDT. CCB is a majority First Nations owned private company carrying on business in the development of packaged goods for health and wellness products.



Terms of the Transaction

Pursuant to the terms of the Letter of Intent announced on January 11, 2021, RDT was to issue 16,666,667 Common Share Units each consisting of one common share and one common share purchase warrant at a deemed price of $0.30 per Unit in exchange for 100% of the common shares of CCB. Each warrant could be exchanged for one common share of the Company at a price of $0.45 per common share for a period of 24 months from the closing of a definitive agreement. Subsequent to this, the terms of the share exchange were modified to reflect the changes in the market price of RDT’s common shares. The value of the transaction remains at $5,000,000 CDN for 100% of the common shares of CCB, however, there are 20,000,000 units issued consisting of one common share and one common share purchase warrant at a deemed price of $0.25 per Unit. Each warrant entitles the holder to acquire one common share of the Company at a price of $0.375 per common share for a two year period from the issuance date.

The common shares issued are subject to an escrow arrangement whereby the shares shall be released over an eleven-month period from closing of the Transaction with the final 20% released at the end of the eleven months. The Amalgamation Agreement allows for a “clawback” of all or a portion of the final release shares upon the occurrence of certain defined events.

In addition, the Amalgamation Agreement allows the CCB selling shareholders the right to nominate one Director to the Board of Directors of RDT. Accordingly, Tom Bryson, the CEO of CCB prior to the Transaction, has agreed to join the Board of RDT effective immediately. Also, the Board of Directors of RDT have offered, and Mr. Bryson has accepted, the further role as President of RDT.



What the acquisition brings to the Company

With the amalgamation complete, CCB becomes a wholly owned subsidiary of RDT. CCB brings CPG and Pharma manufacturing expertise, a Health Canada R&D License with developed proprietary formulations, branded products, several patent pending technologies for rapid onset beverage enhancements and a consortium of strategic alliances including First Nation majority shareholders. The balance sheet of CCB includes $3,000,000 in cash and cash equivalents including a repayable advance of $600,000 to RDT as an advance to closing of the Transaction, equipment, inventory, patent pending technologies and the R&D License. In addition, liabilities in CCB are less than $50,000.



Comments from the Company’s CEO

Mark Upsdell, President and CEO comments on the transaction: “I am delighted with this acquisition – it brings significant benefits to our Company:

  • The cash of $3,000,000 coupled with the proceeds from the Private Placement of $899,842 completed in December, 2020, provides us with the needed cash to ramp up production to meet demand as we enter the Commercialization and Rapid Growth Phase in our development.
  • The expertise, contacts and the assets that come with the CCB amalgamation fit well within our strategy to aggressively expand our product offerings.
  • The new subsidiary will develop, produce and distribute skin creams, topicals, lip balm and shampoos and provide white label services to markets in North America not currently served by RDT. The unique relationship that CCB has with its strategic alliances will continue and be enhanced through combining RDT’s products and licenced production facility with CCB’s channels of distribution.

I am so pleased that Tom Bryson is joining our team both as a Board Member and President. He brings vast experience in commercial enterprises, knowledge of financial markets and, really importantly, the ability to bring people and enterprises together to create value.”



About Tom Bryson

Tom Bryson brings more than 30 years of diversified manufacturing and distribution experience to RDT.   He has been the “lead” on several high-profile Mergers and Acquisitions and is proud to have been a delegate on Canadian Government international trade missions for 20 years. Tom has set up numerous “Greenfield” facilities in Canada, Mexico and the USA. Also, Mr. Bryson is an IP Licensing specialist holding 17 Patent filings.

It is very exciting to see positive results from trials on our Flagship product “QuickStrip” as a delivery method for vaccines, smoking cessation and preventative health care. This builds on the research used to create a new category in the cannabis space that offers a discreet and elegant option to medical and adult recreational users looking for an alternative to conventional delivery methods.

“I am looking forward to the challenges ahead to make RDT a world class organization as the company shifts its focus from clinical research and product development to building its revenue quickly and sustainably.”



About RDT

Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT also provides a turn-key Managed Strip Service Program enabling RDT’s QuickStrip™ proprietary cannabis delivery technology to be licensed to select operators in identified markets. RDT’s service-based annuity contracts drive recurring revenue and facilitate rapid expansion into emerging markets across multiple consumer segments. RDT is committed to continually create innovative solutions for humans, animals, and plants.

For more information, visit: www.rapiddose.ca

For inquiries please contact:

Mark Upsdell Pat McCarthy
CEO Managing Director Capital Markets
[email protected] [email protected]
Ofc (416) 477-1052 Ofc (416) 365-8012



MySize Launches SDK Solution Targeting E-commerce Market With Fully-Customizable PlugIn

The powerful tool will see thousands of e-commerce companies gain the ability to build plug-ins to drive hyper-relevant data-based solutions.

PR Newswire

AIRPORT CITY, Israel, March 8, 2021 /PRNewswire/ — MySize, Inc (the “Company” or “My Size”) (NASDAQ: MYSZ) (TASE: MYSZ), the developer and creator of e-commerce measurement solutions, today announced the launch of their MySizeID E-Commerce Plugin SDK. The SDK enables e-commerce companies to easily create a MySizeID plugin and share it with their customers (online store owners) over their app marketplace. The plugin gives business owners the ability to provide their shoppers the right size for any item every time.

MySize Logo

Until now, e-commerce platforms seeking to capture a share of the estimated $6.5B market have lacked comprehensive sizing solutions. Even MySize customers were dependent on the company’s roadmap and availability when offering the plugin to customers. While the results from MySize’s existing solution included increased shopper engagement, higher conversion rates, and a boost in customer satisfaction, the app’s customizability remained limited.

MySize’s E-commerce SDK solution provides a critical starting point that spares companies from building custom solutions from scratch, taking the burden off of support and research and development teams. By providing developers with a solid base, companies can create the best solutions for themselves in a more time-efficient and cost-effective manner. Users of MySize’s E-commerce SDK Solution can upload their size charts and easily integrate MySizeID’s size recommendation widget into their online store. The sizing solutions created also provide retailers with valuable insights that strengthen the company’s bottom line via a better understanding of its customers.

“We believe the E-commerce SDK Solution is a game-changer that offers tremendous value to allow companies to build hyper-relevant solutions based on data obtained from custom calls,” said Ronen Luzon, CEO, and Founder of MySize. “With e-commerce bigger than ever, it’s critical to empower companies with a flexible set of tools that result in the best and most relevant service for the customers. Having a ton of data available at your fingertips is one thing. Being able to create the right calls to leverage that data in the best way possible is a huge leap forward.”

About MySize Inc:

My Size, Inc. (TASE: MYSZ, NASDAQ: MYSZ) has developed a unique measurement technology based on sophisticated algorithms and cutting-edge technology with broad applications, including the apparel, e-commerce, DIY, shipping, and parcel delivery industries. This proprietary measurement technology is driven by several algorithms that are able to calculate and record measurements in a variety of novel ways. To learn more about My Size, please visit our website: www.mysizeid.com. We routinely post information that may be important to investors in the Investor Relations section of our website. Follow us on Facebook, LinkedIn, Instagram, and Twitter.

Please click here for a demonstration of how MySizeID provides a full sizing solution for the retail industry.

Register here for a trial of MySizeID solution for your online store.

Please click here to download MySizeID for iOS.

Please click hereto download MySizeID for Android.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

U.S. Press Contact:
Strauss Communications
[email protected] 
www.strausscomms.com


IR Contact:

Or Kles, CFO
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/mysize-launches-sdk-solution-targeting-e-commerce-market-with-fully-customizable-plugin-301242422.html

SOURCE My Size Inc.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Re-Opening of the Lead Plaintiff Process in Class Action Lawsuit Against Nutanix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PR Newswire

LOS ANGELES, March 8, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the re-opening of the lead plaintiff process in the class action lawsuit against Nutanix, Inc. (“Nutanix” or “the Company”) (NASDAQ: NTNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between March 1, 2018 and May 30, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before March 22, 2021.         

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Nutanix misled investors about the health of its sales pipeline, customer base, and sales productivity. The truth of the poor state of the Company’s sales prospects was partially revealed over the course of time, causing shares to tumble. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Nutanix, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com 
Office: 310-301-3335
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-action-notice-the-schall-law-firm-announces-the-re-opening-of-the-lead-plaintiff-process-in-class-action-lawsuit-against-nutanix-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301242015.html

SOURCE The Schall Law Firm

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against QuantumScape Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PR Newswire

LOS ANGELES, March 8, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against QuantumScape Corporation (“QuantumScape” or “the Company”) (NYSE: QS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between November 27, 2020 and December 31, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before March 8, 2021.           

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. QuantumScape dramatically overstated the purported success of its solid-state batteries, including their battery power, life, and energy density. The Company was unlikely to scale its battery technology to the multi-layer cells necessary to run electric vehicles. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about QuantumScape, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/deadline-today-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-quantumscape-corporation-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301242098.html

SOURCE The Schall Law Firm

PayPal to Acquire Curv

PR Newswire

SAN JOSE, Calif., March 8, 2021 /PRNewswire/ — PayPal Holdings, Inc. (NASDAQ: PYPL) today announced that it has agreed to acquire Curv to accelerate and expand its initiatives to support cryptocurrencies and digital assets. Curv is a leading provider of cloud-based infrastructure for digital asset security based in Tel Aviv, Israel.

In October 2020, PayPal announced its commitment to help shape the role that digital currencies will play in the future of financial services and commerce. To drive sustained growth and innovation in this area, the company recently created a business unit focused on blockchain, crypto and digital currencies. Curv will join the newly formed group, with its strong team of technologists adding technical expertise to PayPal.

“The acquisition of Curv is part of our effort to invest in the talent and technology to realize our vision for a more inclusive financial system,” said Jose Fernandez da Ponte, vice president and general manager, blockchain, crypto and digital currencies, PayPal. “During our conversations with Curv’s team, we’ve been impressed by their technical talent, entrepreneurial spirit, and the thinking behind the technology they’ve built in the last few years. We’re excited to welcome the Curv team to PayPal.”

Curv was founded in 2018 by CEO Itay Malinger and CTO Dan Yadlin.

“As a pioneer in security infrastructure for digital assets, Curv is proud to be recognized as an innovator and trusted partner to leading financial institutions around the world,” said Malinger. “Now, as the adoption of digital assets accelerates, we feel there’s no better home than PayPal to continue our journey of innovation. We’re excited to join PayPal in expanding the role these assets play in the global economy.”

PayPal expects to complete the acquisition in the first half of 2021. Financial terms of the deal were not disclosed.

About PayPal
PayPal has remained at the forefront of the digital payment revolution for more than 20 years. By leveraging technology to make financial services and commerce more convenient, affordable, and secure, the PayPal platform is empowering more than 375 million consumers and merchants in more than 200 markets to join and thrive in the global economy. For more information, visit paypal.com.

About Curv
Curv is a global trusted provider of digital asset security technology that is delivered as a fully scalable, enterprise-grade and compliant cloud service. Curv’s multi-party computation (MPC) technology simultaneously provides institutions the protection, instant availability and total autonomy over digital assets required to thrive in the digital economy. For more information, visit curv.co.

Forward-Looking Statements
This announcement contains “forward-looking” statements within the meaning of applicable securities laws. Forward-looking statements and information relate to future events and future performance and reflect PayPal’s expectations regarding the impact of this transaction on PayPal’s and Curv’s business and the timing of the closing of the acquisition. Forward-looking statements may be identified by words such as “seek”, “believe”, “plan”, “estimate”, “anticipate”, expect”, “project, “forecast”, or “intend”, and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and any other similar expressions.

Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the statements made, and, accordingly, readers should not place undue reliance on forward-looking statements and information. Factors that could cause or contribute to such differences include, but are not limited to, the timing and satisfaction of closing conditions in connection with the transaction, the possibility that the transaction may not close, the reaction to the transaction of Curv’s customers and business partners, the reaction of competitors to the transaction, the retention of Curv’s employees, PayPal’s plans for Curv, economic and political conditions in the global markets in which PayPal and Curv operate, the future growth of PayPal’s and Curv’s businesses and the possibility that integration following the transaction may be more difficult than expected.

More information about these and other factors that could adversely affect PayPal’s results of operations, financial condition and prospects or that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in PayPal Holdings, Inc.’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission (the “SEC”), and its future filings with the SEC.

The forward-looking statements contained in this announcement speak only as of the date hereof.  PayPal expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Contacts

Investor Relations 

Gabrielle Rabinovitch

[email protected]

Jesse Kreger

[email protected]

Media Relations

Josh Criscoe

[email protected]

Yael Hager

[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/paypal-to-acquire-curv-301242347.html

SOURCE PayPal Holdings, Inc.

Zynex Announces Share Buyback Program

PR Newswire

ENGLEWOOD, Colo., March 8, 2021 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back $10.0 million of the Company’s common stock. The program will commence immediately and is scheduled to terminate on September 8, 2021 or when the $10.0 million buyback limit is reached.

In making the announcement, Zynex President and CEO Thomas Sandgaard stated, “We are committed to delivering shareholder value, and this buyback program authorization reflects the board’s confidence in both our short-term prospects and our long term growth strategy. We believe that the current market value of our shares does not accurately reflect the underlying value of the Company and the buyback program represents an attractive opportunity to deploy capital in a way that will benefit stockholders.”

Under the share buyback program, buybacks may be made from time-to-time in open market and negotiated purchases, effective immediately through the next six months. These buybacks will be made in compliance with the SEC’s Rule 10b-18, subject to market conditions, available liquidity, cash flow, applicable legal requirements and other factors. The specific prices, numbers of shares and timing of purchase transactions will be determined by the Company from time to time in its sole discretion. This program does not obligate the Company to acquire any particular amount of common stock and the program may be suspended or discontinued at any time, including in the event the Company would be deemed to be making an acquisition of its own shares under Rule 13e-3 of the Securities Exchange Act of 1934, as amended.

The Company expects to finance the purchases with existing cash balances, which is not expected to have a material impact on capital levels.

Zynex, Inc. had approximately 36.1 million shares issued and 34.8 million shares outstanding as of March 5, 2021.

About Zynex, Inc.
 
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: Zynex, Inc. (800) 495-6670 

Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/zynex-announces-share-buyback-program-301241947.html

SOURCE Zynex

DISH to acquire Republic Wireless

DISH will acquire all Republic Wireless subscribers and the Republic Wireless brand, subject to regulatory approval

PR Newswire

ENGLEWOOD, Colo., March 8, 2021 /PRNewswire/ — DISH Network Corporation today announced its plans to acquire Republic Wireless, an MVNO service operating on the T-Mobile network. Upon close, DISH will assume approximately 200,000 customer relationships, the Republic Wireless brand and other supporting assets. Once acquired by DISH, Republic customers will not see any immediate changes to their experience or plans, and there is no need for customers to take action.

“Republic has created a loyal following and established a brand known for innovation, customer service and value. We plan to build upon that strong foundation,” said John Swieringa, group president, Retail Wireless and DISH COO. “As we continue to grow our retail wireless business, Republic broadens our existing customer base and positions us to deliver even more value to the market, expanding our portfolio of mobile solutions to meet a variety of customer needs. We look forward to welcoming Republic customers to the DISH family.”

After the acquisition closes, the existing Relay division of Republic Wireless will continue to operate as a standalone company and will become a wholesale customer on DISH’s 5G network. Relay provides communication and productivity solutions for frontline teams in hospitality, facilities management, manufacturing, healthcare and education, and will remain headquartered in Raleigh, NC.

Republic was formed in 2011 with the goal of delivering “wireless service the way it should be.” The business has become known for simple, affordable service with a customer-centric approach to support.

The transaction is subject to customary closing conditions, including regulatory approvals. It is expected to close in the second quarter of 2021. Upon close, Rob Currie, DISH senior vice president of Ting Mobile and MVNO platforms, will lead the Republic Wireless business.


About DISH

DISH Network Corporation is a connectivity company. Since 1980, it has served as a disruptive force, driving innovation and value on behalf of consumers. Through its subsidiaries, the company provides television entertainment and award-winning technology to millions of customers with its satellite DISH TV and streaming SLING TV services. In 2020, the company became a nationwide U.S. wireless carrier through the acquisition of Boost Mobile. DISH continues to innovate in wireless, building the nation’s first cloud-native, Open RAN-based 5G broadband network. DISH Network Corporation (NASDAQ: DISH) is a Fortune 250 company.

Cision View original content:http://www.prnewswire.com/news-releases/dish-to-acquire-republic-wireless-301241950.html

SOURCE DISH Network Corporation

Crown Royal Launches New Ready To Drink Cocktails In A Can

Royal cocktails, made easy, are now available in three delicious flavors

PR Newswire

NEW YORK, March 8, 2021 /PRNewswire/ — With so many of us at home looking for those quality experiences we’ve been missing, Crown Royal is bringing the joy of convenience right to your fingertips. With Crown Royal ready to drink cocktails, it’s never been easier to have a delicious cocktail at home. Still featuring all the exceptional smoothness and quality Crown Royal is known for, you can now effortlessly have a premium experience wherever you are.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8846651-crown-royal-launches-new-ready-to-drink-cocktails-in-a-can/

With our Crown Royal ready to drink cocktails, the gap is bridged between loyal whisky fans and cocktail enthusiasts. With three classic, signature Crown Royal serves to choose from, all offering the quality and deliciousness of a great cocktail, there is something for everyone of legal drinking age, no matter the occasion. Unlike most ready-to-enjoy products, Crown Royal’s whisky beverages are better likened to a cocktail one might order at their favorite bar, canned for the convenience of at-home enjoyment.

“There’s an increasing interest in ready to drink products and there’s a real desire from our drinkers to enjoy the cocktails they’ve always loved at the bar,” said Nicky Heckles, Vice President of Crown Royal. “Whether you’re relaxing in front of the TV or enjoying time in the backyard, Crown Royal ready to drink cocktails are perfect for those who want to celebrate with ease, but not compromise on the premium whisky and flavors we all know and love.”

With three flavors arriving just in time for the summer, consumers 21+ can choose from Washington Apple featuring Crown Royal whisky, apple and sparkling cranberry flavors; Whisky & Cola featuring Crown Royal whisky and cola; and Peach Tea featuring Crown Royal whisky, peach flavor and brewed tea. All three delicious flavors are best served chilled.

Available nationwide, Crown Royal ready to drink cocktails are available for a SRP of $14.99 for a 4-pack of a single flavor and a SRP of $3.99 for a single can.

While you effortlessly enjoy delicious Crown Royal ready to drink cocktails, please do so responsibly.

About Crown Royal 
Crown Royal Canadian Whisky is the number-one selling Canadian whisky brand in the world and has a tradition as long and distinctive as its taste. Specially blended to commemorate a grand tour of Canada made by King George VI and Queen Elizabeth of Great Britain in 1939, Crown Royal’s smooth, elegant flavor and gift-worthy presentation reflect its regal origins – it is considered the epitome of Canadian whisky. For more information, visit www.crownroyal.com. Crown Royal encourages all consumers to please enjoy responsibly.

About Diageo North America                                                       

Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Crown Royal, Bulleit and Buchanan’s whiskies, Smirnoff, Cîroc and Ketel One vodkas, Casamigos and Don Julio tequilas, Captain Morgan, Baileys, Tanqueray and Guinness.

Diageo is listed on both the New York Stock Exchange (NYSE: DEO) and the London Stock Exchange (LSE: DGE) and their products are sold in more than 180 countries around the world. For more information about Diageo, their people, brands, and performance, visit www.diageo.com. Visit Diageo’s global responsible drinking resource, www.DRINKiQ.com, for information, initiatives, and ways to share best practice. Follow at Twitter and Instagram for news and information about Diageo North America: @Diageo_NA.


MEDIA CONTACTS: 

Halley Barnes

Kyra Zeller                                          

TAYLOR

DIAGEO                                                               


[email protected]


[email protected]

 

 

 

Crown Royal Launches New Ready to Drink Cocktails in a Can

 

Crown Royal Whisky & Cola

 

Crown Royal Whisky & Cola 4 pack

 

Cision View original content:http://www.prnewswire.com/news-releases/crown-royal-launches-new-ready-to-drink-cocktails-in-a-can-301241982.html

SOURCE Crown Royal

Blink Charging To Present at the ROTH Virtual Conference

Miami Beach, FL, March 08, 2021 (GLOBE NEWSWIRE) — Blink Charging Co. (Nasdaq: BLNK, BLNKW) (“Blink” or the “Company”), a leading owner, operator, and provider of electric vehicle (EV) charging equipment and services, today announced that Michael D. Farkas, Chief Executive Officer and Michael Rama, Chief Financial Officer, will participate in the ROTH Virtual Conference on Monday, March 15, 2021. Messrs. Farkas and Rama will be available from 9:00 a.m. through 6:00 p.m. for one-on-one and small group meetings via teleconference.

###

About Blink Charging

Blink Charging Co. (Nasdaq: BLNK, BLNKW) is a leader in electric vehicle (EV) charging equipment and has deployed over 23,000 charging stations, many of which are networked EV charging stations, enabling EV drivers to easily charge at any of the Company’s charging locations worldwide. Blink Charging’s principal line of products and services include its Blink EV charging network (“Blink Network”), EV charging equipment, and EV charging services. The Blink Network uses proprietary, cloud-based software that operates, maintains, and tracks the EV charging stations connected to the network and the associated charging data. With global EV purchases forecasted to rise to 10 million vehicles by 2025 from approximately 2 million in 2019, the Company has established key strategic partnerships for rolling out adoption across numerous location types, including parking facilities, multifamily residences and condos, workplace locations, health care/medical facilities, schools and universities, airports, auto dealers, hotels, mixed-use municipal locations, parks and recreation areas, religious institutions, restaurants, retailers, stadiums, supermarkets, and transportation hubs. For more information, please visit https://www.blinkcharging.com/.

Blink Media Contact 


[email protected]

Blink Investor Relations Contact 


[email protected]



AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases

OCALA, Fla., March 08, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen as a potential intranasal therapy. AIM’s ’s goal is to develop Ampligen as a potential intranasal prophylaxis or early-stage treatment for COVID-19 and other respiratory viral diseases.

Centre for Human Drug Research (CHDR), an independent institute located in Leiden in the Netherlands, is conducting the clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.”

The current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and eight placebo subjects, for a total of 40 healthy subjects. The trial is designed to assess the safety, tolerability and biological activity of repeated administration of Ampligen intranasally. The subjects will receive intranasal dosing every other day for 13 days, for a total of seven doses each. AIM is funding the clinical study.

The prior in vitro modeling at The Institute for Antiviral Research at Utah State University demonstrated that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.

Thomas K. Equels, CEO of AIM stated, “We greatly appreciate the tremendous efforts of the entire team at CHDR to help us initiate our Phase 1 study of Ampligen as a potential intranasal therapy. Our objective is to expedite the development of Ampligen as a potential prophylaxis or treatment for COVID-19. Prior results of in vitro modelling were promising, and we are highly encouraged by the potential of an intranasal prophylactic approach using Ampligen to prevent infection and spread of COVID-19. We look forward to providing further updates as this critical trial progresses.”

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company cannot assure that the CHDR study will be successful or yield favorable data and trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 as an intranasal therapy or otherwise, and no assurance can be given that this will be the case. There is the potential for delays in clinical trial enrollment and reporting because of the COVID-19 medical emergency. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: [email protected]

AIM ImmunoTech Inc
Phone: 800-778-4042
Email: [email protected]